ANKEBIO

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise mainly engaged in the research, production, and sales of biopharmaceuticals, and it was among the first companies listed on China's Growth Enterprise Market (GEM). It has successively been recognized as a national innovative (pilot) enterprise, a national technology innovation demonstration enterprise, and one of the top 100 comprehensive manufacturing enterprises in Anhui Province. The company has established several technical platforms, including a nationally accredited corporate technology center, a National-Local Joint Engineering Research Center for precision tumor treatment technologies and products, the Anhui Provincial Bioengineering Laboratory, the Anhui Key Laboratory of Genetic Engineering Pharmaceuticals, and the Anhui Provincial Innovation Center for Precision Tumor Treatment Products. As a leading biopharmaceutical enterprise in Anhui Province, ANKEBIO's current products and services cover a wide range of fields such as biologics, modern Chinese medicine, chemical drugs and small molecule drugs, peptide drugs, in vitro diagnostic reagents, forensic testing, targeted anti-tumor drugs, and cellular immunotherapy. Nearly 20 subsidiaries, including Ankang Yuliangqing, Ankang Hengyi, Shanghai Suhao Yiming, Wuxi Zhongde Meilian, and Xinhua Kun, are distributed across regions such as Anhui, Shanghai, Jiangsu, Zhejiang, and Guangdong. The company has undertaken dozens of national projects, including the "863" Program, the National Science and Technology Key Projects, the National Torch Plan, the National Major New Drug Creation Program, and provincial science and technology key projects. It has independently developed more than 10 national new drugs and has won numerous honors, including two second prizes and one third prize for National Science and Technology Progress Awards, one National Patent Excellence Award, three first prizes, two second prizes, and two third prizes for Anhui Provincial Science and Technology Progress Awards, two Outstanding Contribution Awards from the provincial government, one Major Science and Technology Achievement Award of Anhui Province, and two Gold Medals for Anhui Patents. In the future, the company will continue to adhere to its corporate mission of "Decoding life through science and achieving health with compassion," focusing on its core biopharmaceutical business. Based on its existing product portfolio, the company aims to develop cutting-edge biopharmaceutical technologies such as gene editing, cellular immunotherapy, and oncolytic virus therapy. By providing high-quality products and services, the company seeks to continuously enhance its influence in the pharmaceutical industry and achieve high-quality, sustainable development.